| Therapeutic | Durvalumab |
| Target | CD274 |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK |
| 100% seqID Fv Structure | 5x8m [Fvs: BC], 5xj4 [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5xj4 [Fvs: HL] |
| 100% seqID Structure | 5x8m [Fvs: BC] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2014 |
| INN Year Recommended | 2015 |
| Companies Involved | Advaxis, AIO Studien gGmbH, AstraZeneca, Big Ten Cancer Research Consortium, Canadian Cancer Trials Group, Case Comprehensive Cancer Center, Celgene International SARL, Centre hospitalier de l'Universite de Montreal, Centre Leon Berard, Charite - Universitatsmedizin Berlin, Childrens Hospital Los Angeles, Dana-Farber Cancer Institute, Eli Lilly, Fondazione IRCCS Istituto Nazionale dei Tumori, GlaxoSmithKline, Gradalis, Grand Hopital de Charleroi, Grupo Espanol de Tumores Neuroendocrinos, Gustave Roussy, Immunocore, Innate Pharma, Institut Claudius Regaud, Juno Therapeutics, Kyoto Breast Cancer Research Network, Ludwig Institute for Cancer Research, M. D. Anderson Cancer Center, MedImmune, Memorial Sloan-Kettering Cancer Center, Mirati Therapeutics, Myriad Genetic Laboratories, National Cancer Institute (USA), National Health and Medical Research Council, Northwestern University, Pharmacyclics, Plexxikon, Radboud University, Samsung Medical Center, Spanish Oncology Genito-Urinary Group, Swiss Group for Clinical Cancer Research, UNC Lineberger Comprehensive Cancer Center, UNICANCER, University College London, University of Colorado at Denver, University of Kansas Medical Center, University of Maryland Greenbaum Cancer Center, University of Southern California, University of Sydney, University of Texas M. D. Anderson Cancer Center, VentiRx Pharmaceuticals, Washington University School of Medicine, Yale University, Yonsei University College of Medicine |
| Conditions Approved | Non-small cell lung cancer, Urogenital cancer, Small cell lung cancer |
| Conditions Active | Biliary cancer, Bladder cancer, Cervical cancer, Fallopian tube cancer, Head and neck cancer, Liver cancer, Ovarian cancer, Peritoneal cancer, Renal cell carcinoma, Solid tumours, Breast cancer, Gynaecological cancer, Pancreatic cancer, Acute myeloid leukaemia, Brain metastases, Cholangiocarcinoma, Colorectal cancer, Diffuse large B cell lymphoma, Endometrial cancer, Gallbladder cancer, Gastric cancer, Germ cell and embryonal neoplasms, Glioblastoma, Mesothelioma, Multiple myeloma, Myelodysplastic syndromes, Neuroendocrine tumours, Oesophageal cancer, Oropharyngeal cancer, Prostate cancer, Sarcoma, Soft tissue sarcoma, Chronic lymphocytic leukaemia, Cutaneous T-cell lymphoma, Haematological malignancies, Lung cancer, Lymphoma, Malignant melanoma, Non-Hodgkin's lymphoma, Peripheral T-cell lymphoma, Renal cancer, Gastrointestinal cancer, Myelofibrosis, Vulvovaginal cancer |
| Conditions Discontinued | CNS cancer, Lymphoproliferative disorders, Thyroid cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
